

Important Announcement



Sunovion Pharmaceuticals Canada Inc.,
6790 Century Ave., Suite 100
Mississauga, ON L5N 2V8

Please be advised that during the first half of 2017 there will be some changes to the availability of NIASPAN® (niacin: extended release tablets) and NIASPAN FCT® (niacin: extended-release film coated tablets) which may affect your patients as they seek to renew or refill their prescriptions.

In the event that a patient requires a revised or new prescription for NIASPAN FCT, please note that the following strengths will continue to remain available without change.

AVAILABLE - NIASPAN FCT Tablet Strengths

CONTINUED AVAILABILITY – NO CHANGES

Product Formulation	Tablet Strength	DIN
NIASPAN FCT	500 mg	02309254
NIASPAN FCT	1000 mg	02309289

Provincial Formulary and Private Insurance coverage will remain unchanged. Please see your respective Formulary for details.

During first half of 2017 Sunovion will be discontinuing only the following strengths of NIASPAN and NIASPAN FCT. Please see below for the effected product formulations and their effective discontinuation date.

NIASPAN and NIASPAN FCT Tablet Strengths – TO BE DISCONTINUED in 2017

Discontinued Product Formulations/Strengths

Product Formulation	Tablet Strength	DIN	Effective Discontinuation Date
NIASPAN	500 mg	02262347	March 31 st , 2017
NIASPAN	1000 mg	02262339	June 30 th , 2017
NIASPAN FCT	750 mg	02309262	May 31 st , 2017

If you require further information regarding these changes, or have any questions, please contact Sunovion Medical Information at 1-866-260-6291.



Indications & Clinical Use:¹

NIASPAN FCT (niacin: extended-release film coated tablets) is indicated as an adjunct to diet for reduction of elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B) and triglyceride (TG) levels, and to increase high-density lipoprotein cholesterol (HDL-C) in patient with primary hypercholesterolemia and mixed dyslipidemia when the response to an appropriate diet and other non-pharmacological measures have been inadequate.

Treatment should only be one component of multiple risk factor intervention. Prior to initiating therapy, secondary causes of hypercholesterolemia should be executed and a lipid profile obtained to measure TC, HDL-C and TG.

No studies have been conducted in patients under 21.

For More Information:

Please consult the Product Monograph at <http://www.sunovion.ca/products/index.html> for important information relating to adverse reactions, drug interactions and dosing information which have not been discussed in this communication. The Product Monograph is also available by calling Medical Information at 1-866-260-6291.

1. NIASPAN FCT Product Monograph, October 23, 2015.

NIASPAN® and NIASPAN FCT® are registered trademarks of BGP Products S.a.r.l.
Distributed by Sunovion Pharmaceuticals Canada Inc., Mississauga, Ontario.

SUNOVION and  are registered trademarks of Sumitomo Dainippon Pharma Co., Ltd.

© 2016 Sunovion Pharmaceuticals Canada Inc. All rights reserved.